Sculpting a Better Regimen: The ART of HIV Medications
|
|
- Arthur Fox
- 5 years ago
- Views:
Transcription
1 Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members 2
2 Disclosure This program may contain the mention of drugs or brands presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand or drug. 3
3 Learning Objectives At the end of this session, participants should be able to: 1. Describe characteristics of a complete antiretroviral treatment regimen 2. Explain class-wide side effects and drug interactions of antiretroviral medications 3. Discuss prophylaxis for opportunistic infections and when to initiate 4
4 Overview Epidemiology of HIV Risk factors and diagnosis Initial treatment regimens Antiretroviral medication class reviews Opportunistic infection prophylaxis 5
5 6 Source: Image accessed from
6 Human Immunodeficiency Virus (HIV) in the United States Overview 1.1 million in U.S. living with HIV 1 in 7 unaware that they have HIV 39,513 new diagnoses of HIV in Source: HIV in the United States: at a glance. Centers for Disease Control and Prevention website. Updated 6/9/17. Accessed 9/1/17. Image accessed at
7 8 HIV in the United States, continued
8 Human Immunodeficiency Virus (HIV) HIV vs. AIDS HIV- infection with human immunodeficiency virus AIDS- diagnosed when a person with HIV has CD4 count < 200 cells/mm 3 or an AIDS-defining illness Type of human retrovirus Reverse transcriptase used for viral replication Highly error prone replication Transmission Sexual Parenteral Perinatal 9 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated 11/16/17. Accessed 11/16/17. Image source:
9 HIV Life Cycle 10 Source: Image accessed from
10 Risk Factors for HIV African American, Latino > Caucasian Blood transfusion HIV-1 testing began 1985, HIV-2 in 1992 Men who have sex with men (MSM) Gay or bisexual men = 67% of all HIV diagnoses in United States Intravenous drug users High-risk sexual behavior Percutaneous needle exposure 11 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
11 Estimated Per-Act Probability of Acquiring HIV From an Infected Source by Exposure Act* Source: Imaged accessed at
12 Diagnosis of HIV Diagnostic tests Immunoassays antibody detection 1 st through 4 th generation 4 th generation more sensitive and specific HIV RNA viral count Signs and symptoms Likely asymptomatic Acute retroviral syndrome 13 Source: Sax, Paul. Acute and early HIV infection: clinical manifestations and diagnosis. UpToDate website. Accessed November 13, Image accessed at
13 Goals of Treatment Suppress plasma HIV RNA Preserve immune system function Reduce morbidity and mortality Prevent HIV transmission 14 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
14 Prior to Starting Therapy HIV antibody testing Plasma HIV RNA viral load Genotypic resistance testing CD4 T cell count and percent CBC, CMP, urinalysis Hepatitis A, B and C serologies Fasting blood sugar Lipid panel HLA-B*5701 Pregnancy test 15 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
15 When to Start? Antiretroviral therapy recommended REGARDLESS of CD4 cell count Reasons for deferment Risk for non-compliance Immune reconstitution inflammatory syndrome (IRIS) Increased urgency to initiate Pregnancy AIDS-defining conditions Certain opportunistic infections 16 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
16 Purpose Assess risks and benefits of initiating antiretroviral therapy (ART) in patients with CD4 > 350 cells/mm 3 Methods Multi-national randomized, controlled trial 4,685 treatment-naïve patients Immediate treatment (CD4 > 500 cells/mm 3 ) vs. deferred treatment (CD4 < 350 cells/mm 3 ) 17 Source: Lundgren, et al. N Engl J Med Aug 27;373(9):
17 START Trial Primary outcome Composite of serious AIDS or non-aids events Results Stopped early due to interim analysis results Study subject baseline stats Median VL = 12,759 copies/ml; CD4 = 651 cells/mm 3 Primary outcome (immediate vs. deferred treatment) 1.8% (0.6 events per 100 person years) vs. 4.1% (1.38 events per 100 person years), p< Conclusion Immediate initiation of ART in patients with CD4 > 500 cells/mm 3 showed benefit versus deferred treatment 18 Source: Lundgren, et al. N Engl J Med Aug 27;373(9):
18 What to Start? Many factors to consider in selecting regimen Underlying resistance Treatment experienced vs. treatment naive Patient adherence to regimen Pill burden Side effects Drug interactions Cost 19 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
19 What Constitutes a Complete Regimen? Monotherapy NEVER appropriate Generally, three ACTIVE drugs At least two different drug classes Generally, two NRTIs + one additional agent Can vary with underlying resistance Commonly encountered mistakes Prescribing 2 active medications Failure to properly dose medications 20 Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
20 Antiretroviral Medications* Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Non- Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Protease Inhibitors (PIs) Integrase Strand Transfer Inhibitors (INSTIs) 21 * Not including fusion inhibitors or CCR5 antagonists
21 Recommended Initial Regimens for Most People with HIV 22 Integrase strand transfer inhibitor (INSTI)-based regimens now preferred Durable virologic efficacy Favorable tolerability profiles Ease of use 2 NRTIs + INSTI Lamivudine/abacavir/dolutegravir (Triumeq )* Tenofovir/emtricitabine + dolutegravir (Truvada or Descovy + Tivicay ) Tenofovir/emtricitabine + raltegravir (Truvada or Descovy + Isentress) Tenofovir/emtricitabine/elvitegravir/cobicistat (Stribild or Genvoya ) * if HLA-B*7501 negative Souce: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
22 Recommended Initial Regimens in Certain Clinical Situations Protease inhibitor (PI) and non-nucleoside reverse transcriptase (NNRTI) regimens Overall, effective and tolerable Less favorable drug interactions, side effect profile 2 NRTIs + Boosted Protease inhibitor (PI) Tenofovir/emtricitabine + darunavir + cobicistat or ritonavir Tenofovir/emtricitabine + atazanavir + cobicistat or ritonavir Abacavir/lamivudine + darunavir + cobicistat or ritonavir* Abacavir/lamivudine + atazanavir + cobicistat or ritonavir** * if HLA-B*5701 negative * if HLA-B*5701 negative AND HIV RNA < 100, Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
23 Recommended Initial Regimens in Certain Clinical Situations 2 NRTIs + NNRTI Tenofovir/emtricitabine/efavirenz (Atripla ) Tenofovir/emtricitabine/rilpivirine (Complera )* 2 NRTIs + INSTI Abacavir/lamivudine + raltegravir (Epzicom + Isentress )** * HIV RNA < 100,000 and CD4 > 200 cells/mm 3 ** HLA-B*5701-negative and HIV RNA < 100, Source: Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, 2017.
24 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Incorporate into viral DNA chain Stop viral DNA synthesis 25 Source: Image accessed at
25 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Examples Abacavir (Ziagen ) Lamivudine (Epivir ) Tenofovir disoproxil (Viread ) Emtricitabine (Emtriva ) Tenofovir alafenamide fumarate (Vemlidy ) NRTI combination products ( NRTI backbones ) Lamivudine/abacavir (Epzicom ) Emtricitabine/tenofovir disoproxil (Truvada ) Emtricitabine/tenofovir alafenamide fumarate (Descovy ) 26
26 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Administration With or without food Dose adjustments Typically dosed 1 tablet po q24hr Drug name CrCl 50 ml/min CrCl ml/min CrCl < 30 ml/min Epzicom (abacavir/lamivudine) No dose adjustment Not recommended Not recommended Truvada (tenofovir disoproxil/emtricitabine) No dose adjustment Increase to q48hr interval Not recommended 27 Descovy (tenofovir alafenamide/emtricitabine) No dose adjustment No dose adjustment Not recommended
27 28 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Class-wide side effects Headache Nausea Rash Diarrhea Agent-specific side effects Abacavir hypersensitivity reaction, potential cardiovascular risk Tenofovir decreased bone mineral density, increased SCr, renal failure Drug interactions Potential for renal drug interactions
28 Integrase Strand Transfer Inhibitors (INSTIs) 29 Source: Image accessed from binding
29 Integrase Strand Transfer Inhibitors (INSTIs) Examples Dolutegravir (Tivicay ) Elvitegravir (Vitekta ) Raltegravir (Isentress ) Bictegravir (combo product under priority review) Combination products Abacavir/lamivudine/dolutegravir (Triumeq ) Tenofovir disoproxil/emtricitabine/elvitegravir/ cobicistat (Stribild ) Tenofovir alafenamide fumarate/emtricitabine/ elvitegravir/cobicistat (Genvoya ) 30
30 Integrase Strand Transfer Inhibitors (INSTIs) Administration With or without food Exception Stribild or Genvoya Dose adjustments Drug name Typical Dosing INSTI-experienced or resistance CrCl < 30 ml/min HD Dolutegravir (Tivicay, Triumeq ) 1 tablet PO q24hr 1 tablet PO BID Use with caution Use with caution Elvitegravir (Vitekta, Stribild, Genvoya ) 1 tablet PO q24hr 1 tablet PO q24hr No dose adjustment No dose adjustment Raltegravir (Isentress ) 1 tablet PO BID 1 tablet PO BID No dose adjustment Dose after dialysis 31
31 Integrase Strand Transfer Inhibitors (INSTIs) Class-wide side effects Generally, well-tolerated Increased blood sugar Increased ALT Headache Drug interactions Cation-containing antacids Metformin max dose of 1000mg/day with dolutegravir 32
32 Bictegravir = novel, potent INSTI High in-vitro barrier to resistance Low potential for drug-drug interactions Purpose of trial Assess efficacy and safety of bictegravir/tenofovir/emtricitabine vs. dolutegravir/abacavir/lamivudine Methods Double-blind, multi-center, randomized controlled non-inferiority trial 631 patients randomized to bictegravir (n=316) or dolutegravir (n=315) combination regimens Intention-to-treat analysis 33 Source: Gallant, et al. Lancet Nov 4;390(10107):
33 Study subject baseline stats Median HIV-1 RNA (log 10 copies/ml) % of subjects HIV-1 > 100,000 copies/ml 90% of subjects CD4 cell count 200 cells/ml Results HIV-1 RNA < 50 copies/ml (bictegravir vs. dolutegravir) 92.4% vs. 93% (CI -4.8 to 3.6, p= 0.78) Adverse event profile similar Nausea significantly less in bictegravir (p <0.0001) 34 Source: Gallant, et al. Lancet Nov 4;390(10107):
34 Protease Inhibitors (PIs) 35 Source: Image accessed at
35 Protease Inhibitors (PIs) Examples Darunavir (Prezista ) Atazanavir (Reyataz ) Boosters Cobicistat (Tybost ) Ritonavir (Norvir ) Combination products Darunavir/cobicistat (Prezcobix ) Atazanavir/cobicistat (Evotaz ) 36
36 Protease Inhibitors (PIs) Administration With food Dose adjustments Almost always dosed with booster (cobicistat or ritonavir) Drug name Treatment naïve Treatment experienced Pregnancy Hepatic Impairment (Child-Pugh Class C) Darunavir (Prezista ) 1 tablet PO q24hr 1 darunavir resistance mutation:1 tablet PO BID 1 tablet PO q24hr Use not recommended Atazanavir (Reyataz ) 37 1 tablet (300mg) PO q24hr 1 tablet PO q24hr If on tenofovir or H2RA, use 400mg tablet Use not recommended
37 Protease Inhibitors (PIs) Side Effects Protease Inhibitors Boosters Fat maldistribution Hyperlipidemia Hyperglycemia Skin rash Diarrhea Nausea, vomiting Hyperlipidemia Hyperglycemia Drug interactions Extensive! CYP3A4 inhibitor CYP3A4 substrate 38
38 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Bind to reverse transcriptase enzyme Stop viral DNA replication 39 Source: Image accessed at
39 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Examples Efavirenz (Sustiva ) Rilpivirine (Edurant ) Combination products Tenofovir/emtricitabine/efavirenz (Atripla ) Tenofovir/emtricitabine/rilpivirine (Complera ) Administration Atripla do not take with food Complera take with food 40
40 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Dose adjustments Efavirenz not recommended in moderate-severe hepatic impairment Rilpivirine no dose adjustment for renal or hepatic impairment Agent-specific side effects Efavirenz vivid dreams, rash, dizziness, fatigue Rilpivirine depressive disorder, headache, insomnia 41
41 Opportunistic Infection (OI) Prophylaxis Opportunistic infection (OI) Pneumocystis pneumonia (PCP) Toxoplasmosis gondii When to Initiate OI Prophylaxis CD4 <200 cells/mm 3 CD4 percent <14% Preferred Regimen for OI Prophylaxis Bactrim DS PO daily Toxoplasma IgG Bactrim DS PO positive CD4 <100 cells/mm 3 daily Alternative Regimen for OI Prophylaxis Dapsone 100mg PO daily Dapsone 50mg PO daily + (pyrimethamine 50mg and leucovorin 25mg PO weekly) Mycobacterium avium complex (MAC) CD4 <50 cells/mm 3 (after ruling out disseminated disease) Azithromycin 1200mg PO weekly Clarithromycin 500mg PO BID Azithromycin 600mg PO twice weekly Rifabutin 300mg PO daily 42 Source: Guidelines for the prevention and treatment of opportunistic infections in HIV-1 infected adults and adolescents. AIDS Info website. Updated November 16, Accessed November 16, 2017.
42 43 Questions?
43 References 44 Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US ): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet Nov 4;390(10107): Guidelines for the prevention and treatment of opportunistic infections in HIV-1 infected adults and adolescents. AIDS Info website. Updated November 16, Accessed November 16, Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info website. Updated November 16, Accessed November 16, HIV in the United States: at a glance. Centers for Disease Control and Prevention website. Available at Updated June 9, Accessed September 1, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med Aug 27;373(9): Sax, Paul. Acute and early HIV infection: clinical manifestations and diagnosis. UpToDate website. Accessed November 13, 2017.
HIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More information2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,
More informationExploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More information1/13/16. Updated April 2015
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify
More informationHIV Treatment Update. Objectives. Epidemiology 12/22/2015
HIV Treatment Update Monique Calil, Pharm.D. PGY-1 Resident Broward Health Medical Center Objectives Review antiretroviral therapy (ART) medications used for the treatment of HIV, including new combination
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationThe ART of Antiretroviral Therapy in Critically-ill Patients with HIV
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
NULOESIDE/TIDE REVERSE TRANSRIPTASE INHIBITORS (N(t)RTIs) Abacavir AB (Ziagen) Emtricitabine FT (Emtriva) Lamivudine 3T (Epivir) Tenofovir disoproxil fumarate TDF (Viread) Zidovudine AZT, ZDV (Retrovir)
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationMatters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
More informationStribild, a Single Tablet Regimen for the Treatment of HIV Disease
Comb Prod Ther (2013) 3:1 8 DOI 10.1007/s13556-013-0001-y REVIEW Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Cynthia Brinson To view enhanced content go to www.combitherapy-open.com
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationHAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients. Ellen Kitchell, M.D.
HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D. A Smorgasbord of Possibilities Picking Out A Delicious Meal For Your Patient There are many fantastic options currently
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationClass Review: HIV Antiretroviral Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationJuluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW
Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW Introduction Brand name: Juluca Generic name: Dolutegravir, rilpivirine Pharmacological class: HIV-1 integrase strand transfer inhibitor (INSTI)
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationHIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff
HIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff Dr. Brent J. Pimentel, MD/MPH Texas Program Manager South Central AETC Parkland Health & Hospital System Dallas, TX 1 Objectives
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationHIV IN OKLAHOMA MAKING A DIFFERENCE
HIV IN OKLAHOMA MAKING A DIFFERENCE Madhuri Lad, DO, FACOI, AAHIVS Assistant Program and Medical Director OSU Internal Medicine Specialty Services HIV Program Clinical Assistant Professor Rashes Demographics
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 May 2014 TIVICAY 50 mg, film-coated tablet Bottle of 30 (CIP: 34009 277 146 3 4). Applicant: VIIV HEALTHCARE SAS
More informationClinical Education Initiative THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE Speaker: Antonia Urbina, MD 2/1/2017 The Role of the Primary Care Clinician in HIV Care [video transcript]
More informationThe Role of the Pharmacist in Managing HIV Treatment
The Role of the Pharmacist in Managing HIV Treatment The Role of the Pharmacist in Managing HIV Treatment Linda M. Spooner, PharmD, BCPS (AQ-ID), FASHP, FCCP Professor of Pharmacy Practice Massachusetts
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationJonathan Cohn MD Wayne State University July 24,
Jonathan Cohn MD Wayne State University July 24, 2017 www.matecmichigan.org jcohn@med.wayne.edu Current HIV Test Sequence 4 th Generation Ag/Ab Combo > Differentiation Assay Abbott Architect Alere Determine
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationSOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER. HIV and Oral Health in the Era of Antiretroviral Therapy
SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER HIV and Oral Health in the Era of Antiretroviral Therapy SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER Mark Schweizer, DDS MPH Director of Development
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationEvidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation
Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation November
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationThe ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners
The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners Elizabeth Sherman, PharmD, AAHIVP Faculty South Florida, Southeast AETC Clinical Pharmacist, Memorial Healthcare System Assistant
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationANTIRETROVIRAL (ARV) TREATMENT OF ADULT HIV INFECTION
THERAPEUTIC GUIDELINES ANTIRETROVIRAL (ARV) TREATMENT OF ADULT HIV INFECTION INITIAL RELEASE: SEPTEMBER 2015 UPDATED: MAY 2018 Prepared by: J Montaner (editor), S Guillemi and M Harris (co-editors) on
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationEviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD
Eviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD Population: 8,000,000 Ethnic groups: 75% Jewish 20% Arabs 5% Others HCS PPC 3.5/1000 NPC
More informationOdefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow
Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological
More informationHIV IN PREGNANCY. Practices for Maintaining Maternal Health and Preventing Perinatal HIV Transmission. University of Tennessee Health Science Center
HIV IN PREGNANCY Practices for Maintaining Maternal Health and Preventing Perinatal HIV Transmission Nina K. Sublette, PhD, FNP University of Tennessee Health Science Center College of Nursing: Department
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 ISENTRESS 400 mg, film-coated tablet B/60 (CIP code: 383 084-8) Applicant: MSD-CHIBRET raltegravir
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trogarzo) Reference Number: CP.PHAR.378 Effective Date: 04.17.18 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationMedical Overview March 7, Nina Lambert, NP Inova Juniper Program
Medical Overview March 7, 2019 Nina Lambert, NP Inova Juniper Program Nina.lambert@inova.org Inova Juniper Program Sites Offering medical care, case management and mental health for youth and adults who
More informationLondon Therapeu-c Tender Implementa-on: Guidance for Clinical Use. 14 January 2015
London Therapeu-c Tender Implementa-on: Guidance for Clinical Use 14 January 2015 Contents 2 3. General principles 4. Financial impact of therapeu-c tendering for branded ARVs 5. London ARV algorithm:
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationHIV Clinical Nurse Specialist CCDHB Wellington
RN James Rice-Davies HIV Clinical Nurse Specialist CCDHB Wellington 11:00-11:55 WS #88: Undiagnosed HIV in Your Practice 12:05-13:00 WS #99: Undiagnosed HIV in Your Practice (Repeated) HIV- Undiagnosed
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More information